Pulmonary Vascular Diseases Recommendations
To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
- » Acute thrombo-embolic disease
- » Arteriovenous malformations
- » Hereditary hemorrhagic telengiectasis
- » High-altitude pulmonary vascular diseases
- » Pulmonary arterial hypertension: idiopathic and familial
- » Pulmonary arterial hypertension: pulmonary venous hypertension
- » Pulmonary arterial hypertension: related to collagen vascular disease
- » Pulmonary arterial hypertension: related to portal hypertension, HIV, drugs and toxins, persistent pulmonary hypertension of the newborn
- » Pulmonary hypertension: associated with respiratory system disease
- » Pulmonary hypertension: chronic thrombo-embolic
- » Pulmonary hypertension: miscellaneous causes
The Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES) trial is a large, well-designed clinical study to determine whether addition of imatinib mesylate, a tyrosine kinase inhibitor that targets platelet-derived growth factor (PDGF...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
1 Recommendation, most recent by
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.